10x Genomics (TXG) Invested Capital (2018 - 2026)

10x Genomics' Invested Capital history runs 9 years deep, the most recent figure standing at $814.3 million for Q1 2026.

• In Q1 2026, Invested Capital rose 15.2% year-over-year to $814.3 million; the TTM figure through Mar 2026 stood at $814.3 million (up 15.2% YoY), while the FY2025 annual figure was $796.3 million, up 12.14% from the prior year.
• Invested Capital came in at $814.3 million for Q1 2026 at 10x Genomics, up from $796.3 million in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $814.3 million in Q1 2026 to a low of $706.9 million in Q1 2025.
• A 5-year average of $765.0 million and a median of $775.8 million in 2022 frame the typical range for Invested Capital.
• Across the five-year window, Invested Capital fell 10.41% in 2024 and advanced 15.2% in 2026, its largest moves.
• 10x Genomics' Invested Capital stood at $805.7 million in 2022, then dropped by 8.03% to $741.0 million in 2023, then declined by 4.17% to $710.1 million in 2024, then rose by 12.14% to $796.3 million in 2025, then climbed by 2.26% to $814.3 million in 2026.
• According to Business Quant data, Invested Capital over the past three periods registered $814.3 million, $796.3 million, and $785.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison